TrueCardium® Cardiac Organoids | Exclusively by InSphero (2024)

Mimics the complexity of cardiac tissue with elegant simplicity

TrueCardium® cardiac organoids exhibit critical cardiac functionalities, including synchronized contractility, vascularization, and advanced electrophysiological properties such as Calcium flux. They reflect faithfully the complex cellular composition of cardiac tissue.

Correct physiological response to pharmacological stimuli

The combination of relevant cardiac cell types fosters high-level organoid self-organization and ensures a biologically relevant response to clinical drug challenges. In addition, immune-related reactions can be faithfully reproduced.

Longevity and stability

The cardiac organoids maintain their structural and functional characteristics over a period of 9 months, making them ideal for disease progression and chronic toxicity testing.

Standardized production

Each batch of heart organoids is produced with rigorous consistency, ensuring reliable and reproducible results across different experimental runs. Organoids are cultured and imaged in the automation-compatible Akura™ 96-well and 384-well plates.

Your Success is Our Mission

Schedule a consultation with our experts

Over a maturation time of 35 days in our specialized organoid bioreactors, TrueCardium® organoids develop a complex, yet reproducible range of relevant cell types, including:

• Cardiomyocytes
• Fibroblasts
• Macrophages
• Smooth muscle cells
• Pericytes
• Endothelial cells
• Neurons

During organoid maturation, TrueCardium® Organoids develop a remarkable level of self-organization, including a unique level of vascularization. The cardiomyocytes exhibit polarity, adult rod-shaped structure, and sarcomeric organization.

In addition, TrueCardium® was used in several phenotypic screening projects and prioritized hit-to-lead compounds that were later confirmed to have similar efficacies on other preclinical platforms.

The complex, yet robust and highly uniform tissue morphology of the TrueCardium® organoids enables a more accurate human cardiac tissue model, leading to better predictions in therapeutic discovery and safety assessments. The organoid platform has been tested with a large panel of clinical compounds and has shown responses that have been recapitulated in vivo.

In addition, TrueCardium® was used in several phenotypic screening projects and prioritized hit-to-lead compounds that were later confirmed to have similar efficacies in complementary assays on other preclinical platforms.

TrueCardium® 3D cardiac organoids are transforming the landscape of cardiovascular research and pharmaceutical development by providing a versatile tool for:

• Therapeutic Discovery: Screening for cardiotoxicity and efficacy in early-stage drug development, significantly reducing the risks and costs associated with later-phase failures.
• Disease Modeling: Simulating a range of cardiac diseases such as hypertrophy, fibrosis, and heart failure, facilitating the development of targeted therapies.
• Early-stage cardiac safety: Assessing the therapeutic window of a drug candidate by comparing its effective concentration in the wide range of InSphero’s 3D Microtissue models against safety liabilities in the cardiac organoid.

The adoption of a robust, reproducible, and physiologically relevant cardiac screening platform in preclinical drug discovery represents a pivotal advancement in pharmaceutical research.

By enabling accurate, consistent cardiac safety assessments, this platform significantly reduces the risk of late-stage clinical trial failures due to cardiotoxic effects, which are among the leading causes of drug withdrawals. Moreover, it facilitates the early identification and optimization of promising therapeutic candidates, thereby accelerating the development pipeline and reducing overall costs.

Ultimately, this enhances drug safety and efficacy, offering profound benefits not only to the pharmaceutical industry but also to patients by ensuring quicker access to safer, effective treatments. This platform exemplifies the critical role of innovative technologies in transforming drug discovery, underscoring the need for continuous investment in such tools to propel healthcare advancements.